Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (November 2025)
25 slides from Myomo's investor presentation, November 2025
Slide 1: Investor Presentation November 2025
INVESTOR PRESENTATION NOVEMBER 2025 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and
Slide 3: Strategic Positioning
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strategic Positioning First-Mover Advantage in a Created New Product Large and Growing Market Category with MyoPro with Strong Competitive Myoelectric Orthosis Position Established Direct CMS R
Slide 4: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI ➢ Stroke/CVA ➢ Cerebral Palsy ➢ Traumatic Brain BPI ➢ Multiple Sclerosis Injury PI ➢ ALS ➢ Sp
Slide 5: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, p
Slide 6: Stroke TBI SCI
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Stroke TBI SCI BPI PI 6
Slide 7: Substantial Market Opportunity
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Substantial Market Opportunity Senior Insured Population Up to 50,000 We believe the TAM for Up to patients 600,000 replenish the the MyoPro approximately patients may 46% prevalence doubles wi
Slide 8: Adding Earlier Engagement in Patient Journey
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Adding Earlier Engagement in Patient Journey: ONSET ACUTE SUB-ACUTE OUTPATIENT CHRONIC CARE CARE THERAPY HEMIPARESIS Incidence: (Incidence Population) (Prevalence 800,000 Onset → 1 week 1 week
Slide 9: Reimbursement and Contracting Status
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Reimbursement and Contracting Status HCPCS Codes L8701, L8702 for MyoPro ➢ Issued January 2019 ➢ As of January 1, 2024, these codes are in the brace benefit category, meaning lump sum reimburse
Slide 10: Reimbursement Status: International Markets
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Reimbursement Status: International Markets Germany: Reimbursement for the MyoPro is on a case-by-case basis, with insurance companies often paying for a six-month trial to demonstrate the bene
Slide 11: Newly Published Systematic Review in Support of MyoPro
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Newly Published Systematic Review in Support of MyoPro Results: Ten studies (11 reports) met the criteria; all included individuals post-stroke and one included a post-TBI subset. The majority
Slide 12: Clinical Research: Real-World Evidence from Patient Registry
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Clinical Research: Real-World Evidence from Patient Registry Myoelectric Arm Orthosis Assists Functional Activities: A 3-Month Home Use Outcome Report Results: Statistically significant and cli
Slide 13: Enabling a Paralyzed Arm to Move Again
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Enabling a Paralyzed Arm to Move Again 13
Slide 14: MyoPro Powered Arm Brace: Only Device to Restore Function
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials MyoPro Powered Arm Brace: Only Device to Restore Function ➢ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user’s intention to move via the body’s electromyo
Slide 15: Go-to-Market Approach: How a Patient Obtains a MyoPro
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation Reimbursement MyoPro Custom Delivery & & Evaluation Approval Fabrication Payment Clinical TV, Social Referrals Media New My
Slide 16: Cost-Effective TV Advertising for Target Demographic
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Cost-Effective TV Advertising for Target Demographic 14
Slide 17: MyoPro Growth Plan: Adding New Recurring Patient Sources
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials MyoPro Growth Plan: Adding New Recurring Patient Sources ➢ Adding a New Growth Driver for MyoPro Sales: O&P Clinics and Rehab Hospital Referrals ➢ Until Recently, Most MyoPro Revenue came from
Slide 18: Nationwide Network of MyoPro Centers of Excellence and Rehab Clinic Referral Sources
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials With Reimbursement in Place, We Are Developing a Nationwide Network of MyoPro Centers of Excellence (COE’s) and Rehab Clinic Referral Sources O&P Clinics (COE’s) Payers • Medicare-Accredited Pa
Slide 19: Go-to-Market Model and Channels
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Model and Channels Direct Billing 72% of 3Q25 revenue VA 1% of 3Q25 revenue Myomo In-Country O&P International 18% of 3Q25 revenue Clinics US / O&P Clinics 9% of 3Q25 revenue 19
Slide 20: Key Metrics: Pipeline and Backlog
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Metrics: Pipeline and Backlog Pipeline Backlog: More Fill Units 1800 Increasing Velocity 1669 350 1600 316 300 282 272 1400 1263 249 250 230 1200 208 Total 1000 200 Medicare 800 150 600 100
Slide 21: P&L and Key Balance Sheet Metrics
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual YTD Actual ($000's) Q3'25 Q3'24 2025 2024 Actual Actual ($000's) Q3'25 Q2'25 Revenue $ 10,090 $ 9,208 $ 29,575 $ 32
Slide 22: Key Milestones Driving Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Milestones Driving Revenue Growth Invest in Revenues Direct Billing $M + O&P Channel 40-42 Medicare Part B China JV revenues 32.6 license revenue, Record Record Int’l Int’l Expanded # and V
Slide 23: Current Operating Priorities
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Current Operating Priorities ➢ Grow patient pipeline at a lower cost per Number of Pipeline Adds pipeline pipeline add. 840 adds • Shift advertising media mix 820 800 780 760 ➢ Expand sources o
Slide 24: Leadership Team & Board of Directors
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Barry Camrell Thomas Kirk Chairman & CEO Lead Independent Director VP of QA/RA Scaled multiple te
Slide 25: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 25